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ABSTRACT:
Translation initiation plays a critical role in the regulation of cell growth and 
tumorigenesis. We report here that inhibiting translation initiation through induction 
of  eIF2α  phosphorylation  by  small-molecular-weight  compounds  restricts  the 
availability of the eIF2.GTP.Met-tRNAi ternary complex and abrogates the proliferation 
of cancer cells in vitro and tumor growth in vivo. Restricting the availability of the 
ternary complex preferentially down-regulates the expression of growth-promoting 
proteins and up-regulates the expression of ER stress response genes in cancer cells 
as well as in tumors excised from either animal models of human cancer or cancer 
patients. These findings provide the first direct evidence for translational control 
of gene-specific expression by small molecules in vivo and indicate that translation 
initiation factors are bona fide targets for development of mechanism-specific anti-
cancer agents. 
INTRODUCTION
Translation initiation plays a critical role in both 
general and gene-specific regulation of gene expression 
and  thereby  in  the  control  of  cell  proliferation, 
differentiation,  and  survival.  Unrestricted  translation 
initiation causes malignant transformation in vitro and 
likely plays a causative role in the genesis of some human 
cancers [1-3]. Consistently, translation initiation factors 
are  over-expressed  or  otherwise  activated  in  breast, 
lung,  cervical,  and  hematologic  cancers  and  predict 
poor prognosis [4-9]. In contrast, restricting translation 
initiation reverses transformed phenotypes in vitro and 
in vivo [10-13]. This experimental and clinical evidence 
indicates that translation initiation factors are potential 
targets for the development of mechanism-specific anti-
cancer therapies. Indeed, an anti-sense oligonucleotide-
based therapy targeting eukaryotic translation initiation 
factor (eIF) 4E inhibits tumor growth in animal models 
of cancer and has recently been evaluated in a phase-
I-II  human  clinical  trial[11].  However,  whether  small 
molecules can effectively target translation initiation in 
vivo has not been demonstrated.  The studies reported here 
were designed to determine whether the eIF2.GTP.Met-
tRNAi translation initiation (ternary) complex is a bona 
fide target for the development of anti-cancer therapeutic 
agents.  
Formation  of  the  eIF2.GTP.Met-tRNAi ternary 
complex  is  the  first  critical  step  in  the  translation 
initiation cascade. Upon assembly of the 80S ribosome 
at the initiation codon, GTP in the ternary complex is 
hydrolyzed, releasing the eIF2.GDP binary complex [14]. 
To initiate a new round of translation, eIF2.GDP must 
be converted to eIF2.GTP by eIF2B, the eIF2 guanine 
nucleotide exchange factor. Phosphorylation of the alpha 
subunit of eIF2 (eIF2α) on S51 increases the affinity of 
eIF2 for eIF2B and functionally converts eIF2 into a 
competitive inhibitor of eIF2B[15]. Because of the low 
eIF2B/eIF2 ratio, even partial phosphorylation of eIF2α 
limits  the  amount  of  the  eIF2.GTP.Met-tRNAi ternary 
complex and thereby inhibits translation initiation [16]. 
Restriction  of  the  ternary  complex  by 
phosphorylation  of  eIF2α  plays  a  critical  role  in  the 
translational  regulation  of  specific  genes  or  gene Oncotarget 2013; 4: 1607 www.impactjournals.com/oncotarget
clusters [17-22]. For example, the translation of mRNAs 
containing  excessive  and  stable  secondary  structures, 
like  those  encoding  for  most  oncogenic  proteins,  is 
preferentially down-regulated by phosphorylation of eIF2α 
at levels that would minimally affect translation of most 
housekeeping proteins encoded by mRNAs with simple 
5’UTRs [23-29]. Paradoxically, the translation of a subset 
of mRNAs with particular features in their 5’UTRs, like 
the one coding for activating transcription factor-4 (ATF-
4), is more efficient under conditions that limit the amount 
of the ternary complex [30, 31]. Increased translation of 
ATF-4 results in the transcriptional activation of its target 
genes including the chaperone BiP and the pro-apoptotic 
transcription factor CHOP [32]. 
We previously identified three chemically distinct 
small molecular weight compounds, Clotrimazole (CLT), 
eicosapentaenoic  acid  (EPA),  and  troglitazone  (TRO), 
that cause phosphorylation of eIF2α in non-transformed 
cell lines [18, 20, 22, 33]. We used these compounds as 
molecular probes to determine whether restriction of the 
ternary complex via phosphorylation of eIF2α can be 
achieved pharmacologically for cancer treatment.   
We  report  here  that  CLT,  EPA,  and TRO  cause 
phosphorylation  of  eIF2α,  restrict  the  amount  of  the 
ternary complex, and thereby inhibit translation initiation 
in a wide variety of cancer cell lines.  In experimental 
cancer models, the compounds abrogate xenograft tumor 
growth  and  increase  the  mean  survival  time  of  p53-
/- mice. Abrogation of tumor growth is associated with 
phosphorylation  of  eIF2α,  reduced  availability  of  the 
ternary complex, down-regulation of oncogenes, and up-
regulation of ATF-4-dependent genes. Importantly, we 
show that administration of TRO to liposarcoma patients 
caused phosphorylation of eIF2α and increased expression 
of  the  ATF-4-dependent  protein  BiP.  These  findings 
provide the first direct in vivo evidence that the ternary 
complex can be pharmacologically targeted for cancer 
therapy. 
RESULTS AND DISCUSSION
CLT, EPA, and TRO inhibit cancer cell 
proliferation.  
We determined the effect of CLT, EPA, and TRO 
on the proliferation and/or survival of cancer cell lines by 
sulforhodamine B cell proliferation assay (SRB). Table 1 
presents the IC50 of each compound for the cancer cell 
lines tested. The three molecular probes inhibited in a 
dose-dependent manner the proliferation of a wide variety 
of  cancer  cell  lines,  including  several  multiple  drug-
resistant ones. 
Table 1: Effect of CLT, EPA, and TRO on Ca++ metabolism and proliferation in cancer cells.
CLT TRO EPA
Cell line IC501 Ca++ 
release2
SOC
close2 IC50* Ca++ 
release2
SOC
close2 IC50* Ca++ 
release2
SOC 
close2
KLN
HeLa
Calu-6
MCF-7
ACHN
DU-145
U118MG
HCT 15
SK-OV3
SK-MEL 28
HTB 174
CRL 1933
SV480
HCT 116
HT 29
CRL 231
A549
MMRU
HEP-G2
5
3
1
2
7
7
5
2
12
3
1.5
10
3.4
3
7
2
3
2
5
Y
Y
Y
Y
Y
Y
Y
Y
N 
Y 
Y 
Y 
ND
ND
Y   
ND
Y
Y 
Y 
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
N
ND
ND
ND
ND
Y
Y
Y
8
12
15
10
18
17
34
12
17
30
20
15
14
8
20
26
8
ND
23
Y 
Y
ND
Y
Y
Y
Y
ND
N 
ND
Y
Y 
ND
ND
Y 
ND
Y 
ND
Y 
Y
Y
ND
Y
Y
Y
N
ND
N
ND
N
ND
ND
ND
N
ND
Y
ND
ND
20
10
40
43
62
36
36
47
96
46
79
ND
ND
ND
72
ND
54
36
ND
Y 
Y
Y
Y 
Y
Y
Y 
ND
N
ND
Y
ND
ND
ND
Y 
ND
Y 
Y 
ND
Y
Y
Y
Y
ND
Y
Y
ND
N
ND
N
ND
ND
ND
ND
ND
Y
Y
ND
1Concentration of drug that inhibits cell growth by 50%.
2 Y = yes, N = no, ND = not doneOncotarget 2013; 4: 1608 www.impactjournals.com/oncotarget
CLT, EPA, and TRO deplete internal Ca++ stores 
in cancer cells.
We  have  previously  reported  that  in  NIH  3T3 
cells, CLT, EPA, and TRO release Ca++ from internal 
stores and simultaneously inhibit their refilling through 
store-operated  Ca++  channels  (SOC)  [18,  20,  22,  33].   
This causes phosphorylation of eIF2α and inhibition of 
translation initiation [16, 20, 22]. To determine whether 
inhibition of cancer cell proliferation by CLT, EPA, and 
TRO is mediated by their effect on intracellular Ca++ 
homeostasis,  we  measured  cytosolic  Ca++  in  Fura-2–
loaded cancer cells. Table 1 shows that in most cancer 
cells, particularly those sensitive to their anti-proliferative 
effect, CLT, EPA, and TRO released Ca++ from internal 
stores – as indicated by an increased cytosolic Ca++ in 
Ca++-free media. To determine whether CLT, EPA, and 
Figure 1: CLT, EPA, and TRO cause eIF2α phosphorylation and induce CHOP expression in KLN cells. KLN cells were 
incubated with indicated concentrations of CLT, EPA, and TRO for 2 (A) or 8 (B) hours, the cells were lysed, and equal amounts of protein 
were separated by SDS-PAGE and blotted with anti-PS51-eIF2α, anti-total eIF2α (2 hours treated samples, A) or anti-CHOP and anti-β-
actin (8 hours treated samples, B) specific antibodies.
Figure 2: CLT, EPA, and TRO limit formation of the ternary complex. A) Schematic depiction of expression vector and its 
mRNA products utilized for establishment of a ternary complex availability assay. B) KLN cells stably transfected with this vector were 
incubated with CLT, EPA, or TRO for 24 hours, and reporter activities were determined by DLR (Promega, Inc.). Changes in the F-luc/R-
luc ratio were expressed as multiples of the same ratio in vehicle-treated cells. C) Poly A plus mRNA was isolated from KLN cells in B and 
hybridized with probes specific to F-luc or R-luc mRNA. D) KLN cells were co-transfected with the bi-directional vector shown in Figure 
2A and the eIF2α-WT or eIF2α-51A expression vectors. The F-luc/R-luc ratio in response to CLT, EPA, or TRO was measured by DLR 
assay as in B. E) A single nucleotide was inserted into the second uORF of the ATF-4 5’UTR, which eliminated the ORF2. Cells transfected 
with this mutant construct were treated with CLT, EPA, or TRO, as in 2B.Oncotarget 2013; 4: 1609 www.impactjournals.com/oncotarget
TRO inhibit SOC in cancer cells, we first challenged Fura-
2–loaded cancer cells with thapsigargin (TG), a specific 
inhibitor of SERCA-ATPase [34, 35]. Treatment with TG 
in media containing Ca++ results in sustained elevation of 
cytosolic Ca++, a functional expression of capacitative Ca++ 
influx through SOC. Addition of CLT, EPA, or TRO after 
TG closes SOC in most cancer cell lines, as indicated by 
a sharp reduction of cytosolic Ca++ towards the baseline 
levels  (Table  1).  To  document  directly  whether  the 
compounds release Ca++ from the ER stores, as suggested 
by the FURA-2 experiments, we generated stable cell lines 
that express calcium-indicator cameleon proteins targeted 
to the ER[36]. These experiments formally demonstrate 
that CLT, EPA, and TRO partially deplete ER Ca++ stores 
(see Supplemental Results and in Supplemental Figure 1A 
for details). 
Taken together, the data presented in Table 1 and 
Supplemental  Figure  1A  demonstrate  that  CLT,  EPA, 
and TRO partially deplete ER- Ca++ stores in a variety of 
human cancer cell lines. Because the effect on intracellular 
Ca++ was similar in all cancer cell lines sensitive to the 
anti-proliferative  effect  of  the  compounds,  further 
mechanistic and in vivo studies were conducted in selected 
cancer cell lines.  
Figure 3: CLT, EPA, and TRO inhibit translation initiation in cancer cells. KLN cells were incubated with CLT (A, 15 µM), 
EPA (B, 50 µM), or TRO (C, 30 µM) for 2 hours, lysed, and an equal amount of OD 260 material was separated by sucrose density gradient 
centrifugation. The gradient was eluted from the bottom with constant monitoring at 254 nm.
Table 2: Effect of CLT, EPA, and TRO on cell cycle progression 
of  eIFα-51A/GFP  or  eIF2α-WT/GFP  transfected  KLN-mouse 
carcinoma cells* (the percentage of cells in each cell cycle stage)
Transfected Vector
Treatment
DMSO CLT EPA TRO
eIF2α-WT/GFP
G1: 47
S:    25
G2: 28
G1: 65
S:    19
G2: 16   
G1: 61
S:    22
G2: 17  
G1: 67
S:    21
G2: 12  
eIF2α-51A/GFP
G1: 45
S:    26
G2: 29  
G1: 52
S:    27
G2: 21  
G1: 49
S:    29
G2: 22 
G1: 53
S:    24
G2: 23  
* KLN cells transiently transfected with either GFP-eIF2α-51A (A, B) or GFP-eIF2α-WT (C, 
D) were treated with CLT, EPA, or TRO, sequentially fixed with 3% paraformaldhyde and 
70% ethanol, stained with propidium iodide, and cell cycle distribution of GFP-expressing 
cells was determined by FACS analysis. Oncotarget 2013; 4: 1610 www.impactjournals.com/oncotarget
CLT, EPA, and TRO induce phosphorylation of 
eIF2α and inhibit translation initiation in cancer 
cells.  
Extensive experimental evidence shows that partial 
depletion of ER Ca++ stores induces phosphorylation of 
eIF2α  [18, 20]. As expected from their effect on ER 
Ca++, CLT, EPA, and TRO caused strong phosphorylation 
of eIF2α in KLN squamous cell carcinoma cells (Figure 
1A), as well as in MCF-7 breast cells and DU145 prostate 
cancer cells (data not shown). 
To  determine  the  functional  consequences  of 
eIF2α phosphorylation, we took advantage of the well-
documented  translational  up-regulation  of  ATF-4  and 
consequent  induction  of  ATF-4-responsive  genes  that 
result from eIF2α phosphorylation, which reduces the 
amount of eIF2.GTP.Met-tRNAi ternary complex [32]. As 
shown in Figure 1B, CLT, EPA, and TRO strongly induce 
the expression of CHOP, a transcriptional target of ATF-
4. These data suggest that CLT, EPA, and TRO reduce 
the amount of the ternary complex and thereby inhibit 
translation initiation in cancer cells. 
CLT, EPA, and TRO restrict formation of the 
ternary complex in vitro and in vivo. 
To confirm that CLT, EPA, and TRO restrict the 
abundance of the eIF2.GTP.Met-tRNAi ternary complex, 
we developed a quantitative cell-based assay whose read-
out depends on the availability of this complex. The assay 
takes  advantage  of  the  striking  differential  effect  that 
restriction of the ternary complex exerts on the translation 
of mRNAs. In particular, translation of a subset of mRNAs 
characterized by the presence of multiple upstream open 
reading frames (uORF) in their 5’UTR increases when 
the  ternary  complex  is  restricted,  as  characteristically 
represented by the mRNA encoding for ATF-4 and GCN2 
[32, 37, 38]. Fusion of the 5’ UTR of either mRNA to 
a reporter gene confers enhanced translation when the 
ternary complex is scarce [32, 38].  
Assay development has been described elsewhere 
[39, 40]. Briefly, we constructed a bi-directional plasmid 
in which a common promoter/enhancer complex drives 
the transcription of firefly luciferase (F-luc) ORF fused to 
the 5’UTR of ATF-4, and of the renilla luciferase (R-luc) 
ORF  fused  to  a  simple  90-nucleotide  5’UTR  derived 
from the plasmid (Figure 2A). The relative expression 
of each luciferase was established by the F-luc to R-luc 
ratio determined with a dual luciferase assay. In stably 
transfected KLN cells, CLT, EPA, or TRO increased the 
F-luc to R-luc ratio in a dose-dependent manner without 
affecting the ratio of the respective mRNAs (Figures 2B 
and 2C). These data indicate that CLT, EPA, and TRO 
increase  the  translation  of  the  reporter  F-luc  mRNA 
fused to the 5’UTR of ATF-4. To establish the cause-
effect  relationship  between  phosphorylation  of  eIF2α 
and  the  increased  translation  of  F-luc  mRNA  shown 
Figure 4: CLT, EPA, and TRO cause phosphorylation of eIF2α and induction of BiP and suppress expression of cyclin 
D1 in KLN tumors. Mice with small KLN tumors were treated with CLT (120 mg/kg/day), EPA (2.5.g/kg/day), TRO (350 mg/kg/day), 
or vehicle for one day (left panels) or seven days (right panels). The tumors were excised and stained with antibodies specific to PS51-
eIF2α, BiP, or cyclin D1 and counter-stained with hematoxyline. Oncotarget 2013; 4: 1611 www.impactjournals.com/oncotarget
in  Figure  1,  we  transiently  co-transfected  KLN  cells 
with  the  bi-directional  construct  described  in  Figure 
2A  and  an  expression  vector  coding  for  either  wild-
type eIF2α (eIF2α-WT) or a constitutively active non-
phosphorylatable  eIF2α  mutant  (eIF2α-S51A).  Figure 
2D  shows  that  co-transfection  with  the  eIF2α-S51A 
mutant abrogated the increase in the F-luc to R-luc ratio 
observed in response to CLT, EPA, or TRO, while co-
transfection with eIF2α-WT had no effect. Furthermore, 
a  single  nucleotide  insertion  that  removes  the  second 
uORF in the reporter construct abrogated the translational 
up-regulation of F-luc induced by these agents (Figure 
2E). Abrogation of F-Luc translational up-regulation by 
either non-phosphorylatable eIF2α or by deletion of one 
uORF demonstrates conclusively that CLT, EPA, or TRO 
reduces the availability of the ternary complex by inducing 
phosphorylation of eIF2α. Consistently, anti-cancer agents 
that do not cause eIF2α phosphorylation failed to up-
regulate F-luc (see supplementary Table 1). 
CLT, EPA, and TRO inhibit translation initiation. 
The results depicted in Figures 1 and 2 strongly 
indicate  that  CLT,  EPA,  and  TRO  inhibit  translation 
initiation in cancer cells, a conclusion that can be tested 
experimentally by analyzing polysome profiles of cell 
lysates. When translation initiation is inhibited, polysome 
profiles shift from heavy toward lighter polysomes. As 
shown in Figure 3A-C, the polysome profiles of CLT, EPA, 
and TRO-treated KLN cells shifted from heavy to light 
polysomes and free ribosomal subunits, demonstrating 
that the three agents inhibit translation initiation in cancer 
cells.  This conclusion was confirmed in pulse-labeling 
experiments  demonstrating  that  CLT,  EPA,  and  TRO 
inhibit  protein  synthesis  in  different  cancer  cell  lines 
(Supplemental Figure 1B). 
CLT-, EPA-, and TRO-induced cell cycle arrest 
in cancer cells is mediated by phosphorylation of 
eIF2α.
To determine the effect of CLT, EPA, and TRO 
on  cell  cycle  progression  in  cancer  cells,  we  treated 
exponentially growing KLN cancer cells with these three 
agents, stained them with propidium iodide, and analyzed 
them by FACS for cell cycle distribution and apoptosis. 
CLT, EPA, and TRO blocked the KLN cancer cell cycle in 
G1 with no apparent effect on the proportion of apoptotic 
cells (Supplemental Figure 2). This cell cycle arrest is 
mediated by phosphorylation of eIF2α on S51, because it 
was abrogated in cells transiently transfected with the non-
phosphorylatable eIF2α-S51A mutant (Table 2). 
CLT,  EPA,  and  TRO  cause  phosphorylation 
of eIF2α, induce expression of BiP, and down-
regulate expression of cyclin D1 in tumors.
  To  determine  directly  whether  phosphorylation 
of eIF2α in tumors can be achieved pharmacologically, 
Figure 5: CLT, EPA, and TRO inhibit the growth of tumors and EPA extends the life expectancy of p53-/- mice. A) 
DBA/2J mice were injected with 2.5 x 106 KLN cells, the animals were randomly assigned to the treatment and control groups after 
establishment of tumors and treated with 120 mg/kg/day CLT, or 350 mg/kg/day TRO, both in gum arabica, or EPA (2.5 g/kg, administered 
as fish oil concentrate). Gum arabica-treated mice were used as a control for CLT and TRO, and corn oil-treated mice were used as a control 
for EPA treatment. The experiments were carried out in pairs (CLT vs. gum arabica, TRO vs. gum arabica, EPA vs. corn oil) with 15 mice 
per group. Tumor dimensions were determined with electronic calipers, tumor volume was calculated, and the results were analyzed by 
Student’s t-test. B). Male nude mice were injected with 1x106 human DU145 prostate cancer cells, and mice with visible tumors were fed 
fish oil- or corn oil-enriched diets for five weeks. C) p53-/- mice were treated with either EPA (2.5 g/kg administered as fish oil concentrate) 
or an equicaloric amount of corn oil starting at four weeks of age; the time of death was recorded. The data were analyzed by Kaplan-Mayer 
test (p<0.01).Oncotarget 2013; 4: 1612 www.impactjournals.com/oncotarget
we implanted KLN cells intradermally in mice to form 
orthotopic-syngenic tumors. Mice carrying small (2-4 mm 
in diameter) KLN tumors were treated for either one or 
seven days orally with CLT (120 mg/kg), EPA (2.5 g/kg), 
TRO (350 mg/kg), or the respective vehicles.  Staining of 
excised tumors with anti-PS51-eIF2α−specific antibodies 
showed  that  all  three  agents  induced  significant  and 
sustained phosphorylation of eIF2α, providing the first 
experimental  evidence  that  phosphorylation  of  eIF2α 
in  tumors  can  be  achieved  pharmacologically  (Figure 
4).  Consistently,  in  tumors  from  treated  animals,  all 
three  agents  increased  the  expression  of  BiP,  another 
ATF-4  dependent  surrogate  marker  for  depletion  of 
the ternary complex that is induced by phosphorylation 
of eIF2α[30-32, 41]. CLT, EPA, and TRO also down-
regulated  the  expression  of  cyclin  D1  in  the  tumors 
excised  from  treated  mice  (Figure  4). This  finding  is 
consistent with depletion of the ternary complex, which 
preferentially affects translation of mRNAs containing 
highly structured 5’UTRs, including those encoding for 
most oncogenic  proteins such as cyclin D1[18, 20, 22, 
42]. To  confirm  restriction  of  the  ternary  complex  in 
the tumors, we injected mice intradermically with the 
engineered KLN cells shown in Figure 2B and treated 
tumor-bearing  mice  with  CLT  (120  mg/kg/day)  or 
vehicle for two days. Supplemental Figure 3 shows that 
CLT significantly increased the F-luc to R-luc ratio in 
the tumors from CLT-treated mice. Taken together, the 
experiments described above demonstrate that restriction 
of  the  ternary  complex  and  inhibition  of  translation 
initiation in tumors can be pharmacologically achieved.
CLT, EPA, and TRO inhibit tumor growth in 
animal models.
  To  determine  the  functional  consequence  of 
reducing the amount of the ternary complex in tumors, 
we  treated  KLN-cell  tumor-bearing  mice  orally  with 
CLT (120 mg/kg), EPA (2.5 g/kg), or TRO (350 mg/
kg) daily for 5 weeks. Control mice for CLT or TRO 
received gum arabica (the vehicle used to dissolve the 
drugs), while control mice for EPA received equicaloric 
amounts of corn oil. As shown in Figure 5A, CLT, EPA, 
and TRO significantly reduced the growth of KLN cell 
tumors,  demonstrating  that  phosphorylation  of  eIF2α 
and restriction of the ternary complex is associated with 
inhibition of tumor growth.
The observation that EPA induces phosphorylation 
of eIF2α and inhibition of KLN-tumor growth in vivo 
is remarkable and has major public health implications, 
because EPA, the main n-3 fatty acid in marine fish oil, 
is a component of the human diet. Indeed, some human 
population studies suggest that consumption of diets rich 
in EPA may reduce cancer risk [43-45]. For this reason, 
we probed further the effect of EPA on tumor growth 
and  progression  in  a  DU-145  human  prostate  cancer 
xenograft and in a genetically engineered p53-/- mouse 
cancer model. Treatment with EPA significantly reduced 
the growth of DU-145 human prostate cancer xenograft 
tumors (Figure 5B). In p53-/- mice, oral administration of 
EPA significantly extended the mean survival time from 
185 to 360 days (p<0.005, Figure 5C). This experiment is 
remarkable, because p53 is the most commonly mutated 
or deleted gene in human cancers, and p53-/- mice develop 
Figure 6: TRO induces phosphorylation of eIF2α in human liposarcoma tumors. Biopsy samples of liposarcomas obtained 
before treatment (left panels) and tumor samples of the same patients after treatment with TRO (right panels) in a clinical trial conducted 
independently of our work[46] were stained with antibodies specific to PS51-eIF2α or to BiP.Oncotarget 2013; 4: 1613 www.impactjournals.com/oncotarget
various cancers with 100% penetrance and all die before 
40 weeks of age.  
Troglitazone causes phosphorylation of eIF2α and 
induction of BiP expression in human cancers. 
While this work was in progress, we became aware 
of  a  clinical  trial  in  which TRO  was  administered  to 
liposarcoma patients between a diagnostic biopsy and the 
surgical excision of the tumor [46]. We obtained paraffin-
embedded  pathology  samples  from  these  patients  and 
stained  them  with  anti-PS51-eIF2α-  and  BiP-specific 
antibodies.  Figure  6  shows  that  treatment  with  TRO 
caused a remarkable increase in eIF2α phosphorylation 
and BiP expression in the excised human liposarcoma 
tumors compared with the pre-treatment biopsy.  
Clinical  and  experimental  studies  indicate  that 
dysregulation  of  translation  initiation  plays  a  role 
in  malignant  transformation  and  tumor  progression, 
highlighting  the  potential  of  therapeutics  that  exert 
antitumor and/or chemopreventive effects by selectively 
targeting  the  translation  initiation  cascade[1,  47-
49]. The  findings  reported  in  this  manuscript  provide 
conclusive  evidence  that  translation  initiation  can  be 
pharmacologically targeted in vivo with small molecules, 
a critical prerequisite for the development of translation 
initiation-specific  anti-cancer  agents.  Specifically, 
we  demonstrate  that  1)  pharmacological  agents  that 
induce phosphorylation of eIF2α and reduce the ternary 
complex  in  vitro  similarly  phosphorylate  eIF2α  and 
reduce the ternary complex in animal and human tumors, 
and 2) phosphorylation of eIF2α in vivo is associated 
with suppression of tumor growth and extension of life 
expectancy in various animal cancer models. Direct in 
vivo demonstration of the cause-effect relationship studies 
between induction of eIF2α phosphorylation and tumor 
by replacing endogenous eIF2α with recombinant eIF2α-
S51A mutant could not be carried out despite our attempts 
because tumors formed by these cells failed to grow well 
after an initial phase. Similar results have been reported 
by others [50].
Together,  the  in vivo experiments  depicted  in 
Figure 5 and 6 indicate that pharmacological inhibition 
of translation initiation can be used for cancer treatment 
and perhaps prevention in high-risk populations. Second 
generation  of  translation  initiation  inhibitors  being 
developed as well as progress in resolving the structure 
of translation initiation factors and their regulators should 
accelerate development of translation initiation inhibitors 
for cancer therapy [39, 51, 52]. Furthermore, since EPA 
is the main component of marine fish oils and can be 
readily administered to humans with minimal or no side 
effects, our studies provide a strong favorable rationale 
and the analytical tools for human clinical trials aimed at 
evaluating whether translation initiation inhibitors that 
induce  phosphorylation  of  eIF2α  would  reduce  either 
recurrence in cancer patients who are in remission or the 
incidence of cancer in high-risk populations.   
METHODS
Ethics Statement.
 All animal studies in this report are carried out per 
Harvard Medical School Standing Committee on Animals, 
IACCUC, that oversees protocols involving animals per 
approved protocol #03151. The end point in studies with 
p53-/- and p53+/+ was lifespan. Animals were observed 
daily and weighed twice weekly. They were sacrificed in 
they had locomotion or breathing difficulties or lost more 
than 15% of body weight or appeared cachectic. In all 
other studies, animals were maintained for total of four 
weeks after the start of treatment. They were observed 
at least three times a week, any animal that had tumor 
volume greater than 15% of body weight or lost 15% 
body weight or had breathing or locomotion difficulties or 
other signs of pain or suffering per approved protocol were 
sacrificed. All animals were given analgesic (bprunex) as 
needed.
Human  samples  are  retrospective  discarded 
pathological  materials  with  no  identifiers.  Partners 
HealthCare Human Research Committee, the Partners 
Internal  Review  Board  for  Human  Studies  approved 
the  collection  of  samples  as  de-identified  discarded 
pathological materials not requiring consent. 
Cell growth assay.
Cell growth was measured by the SRB assay as 
described in [22]. 
Measurements of free cytosolic and ERCa++. 
Free intracellular Ca++ was measured using Fura-
2, AM (Molecular Probes, Eugene, OR) as described by 
Clementi et al. [53]. Fluorescence was monitored with 
a  Photon  Technology  International  dual-wavelength 
spectrofluorometer  (PTI,  Monmouth  Junction,  NJ).   
Excitation was at 340/380 nm, and emission at 510 nm. 
For measurement of ER Ca++, we established stable cell 
lines expressing ER-targeted cameleon proteins [36, 54] 
and monitored ER Ca++ using the PTI dual-wavelength 
spectrofluorometer. 
Polysome profiles. 
Polysome profiles were obtained by sucrose density 
gradient centrifugation as described in[55]. Oncotarget 2013; 4: 1614 www.impactjournals.com/oncotarget
Stable and transient transfection.
Cells were seeded at the density of 105 in 60-mm 
(stable transfection) or 106 cells per 150-mm (transient 
transfection) plates and transfected one day later using 
the Qiagen transfectamine transfection kit. For selection 
of stable cell lines, transfected cells were transferred to 
100-mm plates and selected with appropriate antibiotics. 
Cell cycle analysis. 
Untransfected KLN cells were fixed with ethanol 
(70%), stained with propidium iodide (50 µg/ml PI with 
20 µg/ml RNAse A) for 30 minutes, and analyzed by 
FACS[56]. Cells transiently transfected with GFP-eIF2α-
51A or eIF2α-WT were fixed with 3% paraformaldhyde, 
washed twice with PBS, fixed again with 70% methanol, 
and  stained  with  PI  as  described  above.  Cell  cycle 
distribution  of  GFP-expressing  cells  was  analyzed  by 
FACS.
Western blotting. 
Cell extracts were separated by SDS-PAGE and 
probed with anti-phosphoserine-51-eIF2α (PS51-eIF2α), 
anti-total  eIF2α-specific  antibodies  (PS51-eIF2α) 
(Biosource International, Hopkinton, MA), anti-CHOP, or 
anti β-actin as described [56].
Animal studies.
 KLN squamous cell carcinoma cells were injected 
intradermically (2.5 x 105 cells in 0.1 ml of PBS) into 
6-week-old female DBA/2J mice (Jackson Laboratories, 
Bar Harbor, ME). Four days after implantation, tumor-
bearing mice were randomized into control and treatment 
groups and then treated with the vehicle or CLT (120 mg/
kg in gum arabica), TRO (400 mg/kg in gum arabica), or 
EPA (2.5 g/kg, lipid concentrate) daily by gavage. Control 
mice were treated with the respective vehicle alone. Tumor 
volumes were calculated as in [20] and results analyzed 
by Student’s t-test. DU145 human prostate cancer cells 
were subcutaneously injected to nude mice that were fed 
a diet containing either 20% corn oil or 1% corn oil and 
19% menhaden oil, starting five days after inoculation of 
tumors. Tumor volumes were calculated[20] and results 
analyzed by Student’s t-test. p53-/- mice were administered 
either EPA (2.5 g/kg in fish oil refined for high content 
of EPA) or equicaloric corn oil daily by gavage until the 
death of the last animal.  Life expectancies of control and 
EPA-treated mice were compared by Kaplan-Meyer test.
The end point in studies with p53-/- and p53+/+ 
was lifespan. Animals were observed daily and weighed 
twice weekly. They were sacrificed in they had locomotion 
or breathing difficulties or lost more than 15% of body 
weight or appeared cachectic. In all other studies, animals 
were maintained for total of four weeks after the start of 
treatment. They were observed at least three times a week, 
any animal that had tumor volume greater than 15% of 
body weight or lost 15% body weight or had breathing or 
locomotion difficulties or other signs of pain or suffering 
per approved protocol were sacrificed. All animals were 
given analgesic (bprunex) as needed.
Immunocytochemistry.
Formalin-fixed, paraffin-embedded tumor sections 
were immunostained with anti-PS51-eIF2α, anti-BiP, and 
anti-cyclin  D1  antibodies  (Santa  Cruz  Biotechnology, 
Santa Cruz, CA), and counter-stained with hematoxylin.
Dual luciferase assay.
Cells or minced tumors expressing F-luc and R-luc 
were lysed and the extracts assayed with a glow-type dual 
luciferase assay kit, (Promega, Inc., Madison, WI).
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